Serum Institute of India will spend over $100 million to build manufacturing capacity for the M72/AS01E tuberculosis vaccine. The initiative focuses on scaling up production for the Phase III trial candidate to ensure global availability if it gains regulatory approval. This partnership with Gates MRI targets the high burden of tuberculosis in countries like India, South Africa, and Kenya.
Serum Institute of India (SII) is preparing for the potential launch of a new tuberculosis vaccine by investing more than $100 million into its manufacturing infrastructure. The company has entered into a strategic partnership with the Gates Medical Research Institute (Gates MRI) to produce the M72/AS01E vaccine candidate. This move is designed to ensure that if the vaccine passes its final clinical stages, it can be manufactured in large quantities and distributed efficiently to countries where tuberculosis remains a major health crisis.
Scaling Production Ahead of Approvals
The decision to begin technology transfer and manufacturing preparations while the vaccine is still in Phase III clinical trials is a calculated strategy. By readying its facilities now, SII aims to remove the usual time gap between receiving regulatory approval and reaching patients in need. The agreement involves transferring complex manufacturing know-how for the vaccine antigen, while GlaxoSmithKline (GSK) will supply the necessary AS01E adjuvant. This collaborative effort is intended to speed up the supply chain as soon as success is confirmed.
Clinical Progress and Global Impact
The M72/AS01E candidate is currently undergoing a massive Phase 3 clinical trial involving 20,000 participants across Africa and Indonesia, with full enrollment achieved in April 2025. Earlier results from Phase 2b studies showed the vaccine offered about 50% protection against active pulmonary tuberculosis in specific adult groups. Public health experts suggest that a vaccine with this level of effectiveness could prevent millions of new infections over the coming decades, making this one of the most closely watched developments in global infectious disease control.
Strategic Role in Global Healthcare
For investors and observers of the biotech sector, this project highlights Serum Institute’s established strength in producing WHO-prequalified vaccines at a large scale. While this investment focuses on global access and public health, it also reinforces the company’s position within the international vaccine supply network. Plans are already in place to involve local manufacturers in Indonesia and South Africa, which may help diversify the supply chain and reduce logistical bottlenecks in the future.
The key monitorable for investors will be the results of the ongoing Phase 3 trial and subsequent regulatory filings. Because the manufacturing investment is being made ahead of final trial success, the financial impact will depend heavily on the clinical outcomes and the speed of regulatory approvals in different markets. Future updates regarding trial milestones or potential production timelines from SII or the Gates Foundation will be the next important indicators for this project.